Background: The optimal dosage of erythropoietin stimulating agents (ESAs) seems to be highly variable. However, the safety of this group of drugs at inappropriately high doses is a major concern, making early detection of ESA resistance desirable. Aim: To determine both the occurrence and causes of resistance to ESAs in haemodialysis patients, in order to optimise the effect based on the clinical outcome. Method: Design: Cross-sectional, retrospective study. Setting: County hospital. Sample of study: Patients on haemodialysis and treated with ESAs for anaemia associated with chronic kidney disease, for a minimum of 3 months. Study variables: Age, gender, type of ESA and dosage, haemoglobin levels (Hb, g/dl) and resistance index (ERI) calculated as ESA dose (IU)/weight (kg)/week divided by a given value of Hb concentration (g/dl) and used to establish the relationship between the dose and effectiveness (Hb: 11-12 g/dl)(1).
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Main potential risk factors assessed for resistance: Kt index (haemodialysis adequacy), serum ferritin (ng/dl), transferrin saturation (TS, %), intact parathyroid hormone (iPTH, pg/ml), C-reactive protein (CRP, mg/l), comorbidity and other medications. Results: Forty-eight patients (60.4 % male) were treated with ESAs for almost 8 months. Median age was 66.9 years (range 28-84). Most patients (86.6 %) received epoetin b and 13.4 % darbepoetin a. Only 17 patients received recommended doses (B125 IU/kg/week): six reached Hb target, nine overdosed (Hb [ 12 g/dl), and two had Hb \ 11 g/dl, both of whom presented two risk factors: low TS and high CRP levels. Thirty-one patients received [125 IU/kg/week: six reached Hb target, twenty overdosed, and five had Hb \ 11 g/dl. These five were found to be resistant according to ERI and the risk factors observed were: one inadequate Kt index; all presented low serum ferritin (\100 ng/ml) and TS (\20 %). High iPTH levels were found in four patients and high CRP levels in three. Only one case of diabetes mellitus was observed. Conclusion: Most patients exceeded the upper limit of the recommended target Hb. Five patients were found to be resistant, with at least low serum ferritin as risk factors. Individual evaluation of ESA resistance should be conducted in haemodialysis patients.
